Two of Flagship Pioneering's AI biotechs will join forces in a merger to advance an early-stage pipeline, as well as continue a series of big-name partnerships already in tow.
After their merger, Valo Health and Montai Therapeutics will operate under the Valo brand. Flagship launched Valo in 2020 with almost $100 million in financing and a mission to use AI to speed up drug development across oncology, neurodegenerative and cardiovascular arenas.
Montai, also a Flagship outfit, got its start in 2022 with an initial investment of $50 million. The company’s pipeline includes a phase 1-stage oral NRF2 agonist for ulcerative colitis, dubbed MTAI-1025, as well as preclinical and discovery-stage programs aimed at immunological and respiratory conditions.
Both companies have built a bevy of partnerships throughout the life sciences realm. Valo linked up with Germany's Merck KGaA last year in a Parkinson's disease-focused deal worth up to $3 billion, as well as signing agreements with the likes of Novo, Pfizer and global CRO Charles River Laboratories.
Meanwhile, Montai also teamed up with Pfizer through Flagship in 2024 to identify small-molecule candidates for non-small cell lung cancer, and has collaborated with chipmaking giant NVIDIA for technology access.
Specific terms of the merger between Valo and Montai remain under wraps. The enlarged Valo will advance a pipeline led by Montai's MTAI-1025 and its oral STAT6 inhibitor for atopic dermatitis, as well as continue their array of established partnerships, according to Brian Alexander, M.D., CEO of Valo and a CEO-partner at Flagship, who will continue to lead the company.
“This merger creates a single company with complementary platforms, a growing pipeline, established biopharma partnerships and a clear path to its next stage of growth,” Alexander said in a Nov. 11 release. “Valo and Montai share a core philosophy that human evidence should drive drug discovery, making this a compelling opportunity to bring complementary technology and programs together while maintaining momentum across the portfolio.”
Bringing together the two AI platforms will grant the companies wider access and development capabilities, according to Margo Georgiadis, Montai CEO and also a CEO-partner at Flagship.
“Joining Valo allows us to apply our platform to more targets across [immunology and inflammation] and broader therapeutic areas, as well as ensuring the right targeted patient populations for our programs,” Georgiadis said.
The role of AI in drug development is one of the hot topics being discussed at Fierce Biotech's high-impact event in London this month. Find out more information and register by clicking on the banner below:
